Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Citizens & Northern Corp

Citizens & Northern Corp trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,230 shares of the biopharmaceutical company’s stock after selling 882 shares during the quarter. Citizens & Northern Corp’s holdings in Bristol-Myers Squibb were worth $987,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Addison Advisors LLC grew its position in Bristol-Myers Squibb by 6.6% in the 3rd quarter. Addison Advisors LLC now owns 3,120 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 192 shares in the last quarter. Symphony Financial Ltd. Co. grew its position in shares of Bristol-Myers Squibb by 4.1% during the third quarter. Symphony Financial Ltd. Co. now owns 4,980 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 194 shares in the last quarter. AMG National Trust Bank grew its position in shares of Bristol-Myers Squibb by 1.0% during the third quarter. AMG National Trust Bank now owns 19,685 shares of the biopharmaceutical company’s stock worth $1,143,000 after buying an additional 201 shares in the last quarter. Westside Investment Management Inc. grew its position in shares of Bristol-Myers Squibb by 2.9% during the fourth quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 204 shares in the last quarter. Finally, Fulton Breakefield Broenniman LLC grew its position in shares of Bristol-Myers Squibb by 4.6% during the fourth quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 209 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Price Performance

NYSE BMY traded down $0.80 on Thursday, reaching $41.54. 9,437,940 shares of the stock traded hands, compared to its average volume of 15,470,135. The firm’s fifty day simple moving average is $48.24 and its 200 day simple moving average is $49.80. The company has a market cap of $84.21 billion, a price-to-earnings ratio of -13.45, a P/E/G ratio of 14.31 and a beta of 0.45. Bristol-Myers Squibb has a 12 month low of $41.51 and a 12 month high of $66.69. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 earnings per share. As a group, research analysts predict that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.78%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of research reports. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. Barclays decreased their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Wells Fargo & Company raised their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. Finally, BMO Capital Markets cut their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.